Swedencare stock
SECARE.STSTOSwedencare AB (publ), HealthcareISIN SE0015988167
51Score 51 out of 100, Neutral
Price and trend
41 / 100
Price history
−45% in one yearThe chart shows daily closes over 10 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 18% below it.
Since July 2024 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 50% below its 52-week high. Largest decline in 10 years: 88% (September 2021 to October 2026).
Chart figures for advanced users
- SMA 50$2.12
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$2.39
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.89
- The lowest closing price of the last twelve months.
- Resistance$3.94
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Swedencare AB (publ) belongs to the Medical (Pharmaceuticals) industry (Sweden) and, with a market value of $312.54M, is number 15 of 15 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $270.19M (up 6.1% year on year) and earnings of $5.57M (down 43.9%).
- MEQIRI Score 51 out of 100 (Neutral): rank 368 of 702 in Healthcare, median 53.
Show more
- The P/E is 36 (Medical (Pharmaceuticals) median 35.7, own median of recent years 50.4).
- Our model puts fair value at $2.52, with the price 23% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 62.2% a year since 2020, Medical (Pharmaceuticals) median 12.8%.Growth 74
- Analysts expect strong earnings growthUp 40.9% a year through 2028 (estimates from 2 analysts).Growth 74
- Earnings turn into cashFree cash flow 251% of earnings over the last 12 months.Fundamentals 79
Weaknesses
- DilutionShare count up 84% since 2020.Capital allocation 28
- Interest barely coveredOperating profit covers interest only 1.9 times.Stability 61
- Margin fallingOperating margin 5.3%, average of the prior years 8.4% (to 2024).Profitability 35
Its standout strengths are fundamentals and growth, while capital allocation and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 52 to 51.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak momentum
What lowers it
- price not overheated over the past year
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $1.80 and expensive above $4.21 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $3.11 (cash-flow model) and $1.94 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.4%. At 9.4% the fair value would be $2.31, at 7.4% it would be $2.82.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (35.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 2.9% on the twelve months before. Revenue has grown strongly since 2013, at around 52% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating 5%, net 2%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 21 Oct 2026EPS reported $0.02 (expected $0.03)below expectations
Analyst estimates
- Earnings per share
- $0.08−17.4%
- Revenue
- $282.35M−1.2%
- Earnings per share
- $0.14−7.3%
- Revenue
- $308.52M−1.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −16.4%As previously communicated, a stronger second half is expected in North America after a disappointing second quarter there.
“Europe and Production segments delivered standout organic growth while North America was disappointing but is expected to, as previously communicated, strengthen in H2 and as delayed launches, online and big box initiatives scale up.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 22 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Swedencare
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 51
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Pharmaceuticals)
The next larger companies by market value
- Corcept TherapeuticsCORT $8.07B75
- Kiniksa Pharmaceuticals InternationalKNSA $7.56B68
- Tsuruha Holdings3391.T $7.1B62
- MatsukiyoCocokara3088.T $6.71B75
- Abbott IndiaABBOTINDIA.NS $6.01B75
- LiquidiaLQDA $5.24B43
- Prestige Consumer HealthcarePBH $2.15B56
- CosmoCMHC.SW $1.21B37
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 13 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.